糖酸通过调节SNARK/AMPK信号通路来保护高葡萄糖诱导的淋巴细胞
Tian-Qi Zhao1, Yuan Li2, Miao Zhang3
1School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, China.
Current medical science
|July 14, 2023
概括
甘酸 (GA) 通过激活AMPK通路,减少纤维化和炎症,保护脏细胞免受高葡萄糖损伤. 抑制SNARK蛋白会使这些效应恶化,突出显示GA.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 糖尿病病是一种糖尿病的主要并发症,其特征是状硬化症.
- 足细胞损伤和纤维化是糖尿病病的关键病理特征.
- 腺5'-单酸盐激活蛋白激酶 (AMPK) 途径与细胞保护有关.
研究的目的:
- 调查糖酸 (GA) 对高葡萄糖诱导的细胞损伤的保护机制.
- 通过AMPK/糖糖非发酵AMPK相关激酶 (SNARK) 信号通路来确定GA是否具有抗纤维和抗炎作用.
主要方法:
- 细胞被SNARK siRNA感染.
- 基因和蛋白质表达分析使用实时定量PCR,免疫光学,西式涂抹和ELISA.
- 评估了纤维化 (TGF-β1,α-SMA) 和炎症 (NF-κB,IL-6,TNF-α) 的关键因素.
主要成果:
- 糖酸 (GA) 调节AMPK通路,降低细胞中的纤维化相关因素.
- 斯纳克siRNA转染抑制了AMPK通路,导致纤维化和炎症的增加.
- GA治疗降低了炎症标志物,而SNARK敲击会加剧炎症.
结论:
- 甘酸 (GA) 通过AMPK信号通路保护细胞免受高葡萄糖诱导的纤维化和炎症.
- 在这种途径中,SNARK起着至关重要的作用;其抑制会加剧细胞损伤.
- GA代表了糖尿病病的潜在治疗剂.
相关概念视频
01:25cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
01:23Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
01:28Glomerular Filtration Rate and its Regulation
3.0K
The Glomerular Filtration Rate (GFR) is a measure of kidney function, reflecting the volume of filtrate formed per minute in the kidneys. On average, GFR is approximately 125 mL/min in males and 105 mL/min in females. Maintaining a relatively constant GFR is essential for the kidneys to effectively regulate body fluid homeostasis and maintain extracellular stability.
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
3.0K
01:09GPCRs Regulate Adenylyl Cylase Activity
5.7K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.7K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208
01:24Glucagon-like Receptor Agonists
364
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
364